若生智能
Drug Database
TJ

TJ-15 (OGT)

✓ Approved

Tsumura · 治疗药物

什么是 TJ-15？

TJ-15 是一种治疗药物，由Tsumura研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名OGT
公司Tsumura
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Tsumura

治疗适应症

TJ-15 针对 5 个适应症，涉及 5 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersEczema✓ Approved
Gastrointestinal disordersGastritis✓ Approved
Vascular disordersHypertension✓ Approved
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Nervous system disordersCerebral cyst haemorrhage✓ Approved

相关研究文献

PubMedInfectious diseases and therapy2026-08-06

Elevated Plasma GDF-15 Levels are Associated with the Immune Non-Responder Phenotype in People with HIV.

López López Aida A, Alonso Domínguez Jacobo J, Martínez Barros Inés I, Pérez González Alexandre A et al.

Most people with HIV (PWH) achieve immune recovery with antiretroviral therapy (ART); however, a clinically relevant subset, known as immune non-responders (INRs), fails to restore CD4+ T-cell counts despite sustained virological suppression and shows persistent immune dysfunction. Growth differentiation factor 15 (GDF-15), a stress-responsive cytokine associated with inflammation, aging, chronic disease, and multimorbidity, has not been characterized across distinct HIV viro-immunological phenotypes. We conducted an exploratory cross-sectional study including 80 PWH classified as ART-naïve individuals, virally suppressed INRs, elite controllers (ECs), and ART-treated immune responders (IRs), as well as 20 HIV-negative controls. Plasma GDF-15 levels were measured by immunoassay. Associations with log-transformed GDF-15 concentrations were assessed using multivariable linear regression including age, CD4+ T-cell nadir, and INR status. INRs showed the highest plasma GDF-15 levels (median, 1143.9 pg/ml), significantly exceeding those observed in ART-naïve individuals, ECs, IRs, and HIV-negative controls (all p ≤ 0.002). GDF-15 levels correlated positively with age, time since HIV diagnosis, and ART duration, and inversely with CD4+ T-cell nadir and the CD4/CD8 ratio (all p ≤ 0.001). In adjusted analysis, INR status remained independently associated with higher log-transformed GDF-15 levels (β = 0.271, 95% CI 0.062-0.480; p = 0.012), corresponding to 31.1% higher GDF-15 concentrations relative to non-INR participants. Plasma GDF-15 levels were higher in virally suppressed INRs than in other viro-immunological groups and remained independently associated with INR status after adjustment for selected covariates. These findings support further investigation of GDF-15 as a potential biomarker of incomplete immune recovery and residual biological stress in virally suppressed PWH. Prospective studies are warranted to validate its clinical and pathophysiological relevance.

PMID 42557437
阅读全文 →
PubMedBritish journal of biomedical science2026-08-06

Pleiotropic effects of GDF-15 to regulate nutritional status: perspectives from body composition to nutrition-related disorders.

Peng Binbin B, Zhao Wei W, Kong Ming M, Chen Yu Y et al.

Growth differentiation factor 15 (GDF-15), a stressful cytokine of the transforming growth factor-β (TGF-β) superfamily, plays pivotal roles in diverse physiological and pathological processes. Most recently, its pleiotropic effects regarding energy metabolism and nutritional modulation are of intense scrutiny. Its physiological functions involve signaling pathways such as GDF-15/glial cell-derived neurotrophic factor family receptor α-like protein (GFRAL)/rearranged during transfection (RET), phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (Akt)/mammalian target of rapamycin (mTOR), nuclear factor kappa B (NF-κB), and reactive oxygen species (ROS). The mechanism of action involves regulation of energy metabolism, inflammation, oxidative stress, and muscle-fat-bone metabolism, and it holds important prognostic value and potential therapeutic significance. Mounting evidence has suggested that GDF-15 levels are significantly increased in the context of cancer cachexia, metabolic syndrome (MetS), and amongst older patients, paralleling multiple indicators of nutrition. Notably, this association appears to be gender- and age-specific, therefore serving as a good biomarker alongside a therapeutic target to mitigate or even reverse disease-related nutritional deficiency and aggravation. However, the precise contribution of GDF-15 to evaluate nutritional status and its mechanistic basis across varying disorders is not fully elucidated. In light of these knowledge gaps, we sought to delve into basic research, clinical information and translational evidence, aiming to analyze the molecular regulatory network of GDF-15 and clarify its clinical implications as a novel diagnostic tool and assessment metric, and in turn provide a theoretical basis for early intervention and personalized treatment. Future research should focus on elucidating GDF-15's neuroanatomical basis and signaling pathways, validating gender-disparity mechanisms, establishing clinical diagnostic thresholds, optimizing targeted therapeutic strategies, and developing dynamic monitoring approaches, so as to bridge the gap from biomarker discovery to precision intervention.

PMID 42558428
阅读全文 →
PubMedTherapeutic advances in reproductive health2026-08-06

Predictors and barriers to family planning access through pharmacies and drug shops among young women (15-24 Years) in Debre Tabor Town: A Convergent Parallel Mixed-Method study.

Zerihun Tigabu Eskeziya TE, Mussie Desalegn Addis DA, Kassaw Abel Temeche AT, Agidew Melaku Mekonnen MM et al.

Pharmacies and drug shops offer a valuable opportunity to improve access to family planning for adolescents and young women. However, challenges still exist that hinder their ability to obtain these services through such outlets. This study aimed to identify the factors influencing and barriers to accessing family planning services among adolescent girls and young women aged 15-24 years in Debre Tabor Town. Convergent Parallel Mixed-Method study. Adolescent girls and young women aged 15-24 were selected through simple random sampling, while key informants were purposively chosen. A structured questionnaire was used for quantitative data collection, and qualitative data were obtained via key informant interviews. Quantitative data analysis was conducted using STATA version 15, whereas qualitative data were analyzed manually through thematic analysis. A total of 384 adolescent girls and young women took part in the study, with an average age of 20.74 years. About 41.7% were aged 22-24, while 17% were between 15 and 18 years. Overall, 65.4% reported having access to family planning services. However, those aged 22-24 were 5.6 times more likely to access these services than those aged 15-18 (AOR = 5.6, 95% CI: 1.79-17.38). Additionally, young women who lacked privacy when accessing services were 53% less likely to utilize family planning than those who had privacy (COR = 0.47, 95% CI: 0.11, 1.83). Furthermore, individuals from cultures that disapproved of family planning were 44% less likely to seek these services than those from accepting cultures (COR = 0.44, 95% CI: 0.14, 1.87). Age and sexual activity were significant predictors of access to family planning services. Conversely, barriers such as the cost of contraceptives, lack of privacy, and cultural disapproval hindered young women from using these services through pharmacies and drug shops.

PMID 42558758
阅读全文 →
PubMedBreast cancer research and treatment2026-08-06

Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes.

Voorthuis R A B RAB, Opdam M M, Ter Hoeve N D ND, Silva M da MD et al.

Invasive lobular carcinoma (ILC) of the breast typically affects older women. As a result, there is limited research on prognosis and prognostic factors in young women with ILC. Here we set out to determine the long-term outcome and prognostic factors of women under 40 years of age with lymph node-negative (N0), hormone-receptor positive (HR+)/human epidermal growth-factor receptor 2 negative (HER2-) ILC who did not receive adjuvant systemic treatment (chemo- and/or endocrine therapy). Through the Netherlands Cancer Registry we selected all systemically untreated patients younger than 40 years with HR+/HER2-, N0, early breast cancer diagnosed in the Netherlands from 1989-2000. At the time, node-negativity was considered a favorable prognostic marker and guidelines recommended no adjuvant systemic therapy for this subgroup. Distant recurrence-free survival (DRFS), recurrence-free survival (RFS) and overall survival (OS) were assessed according to the STEEP criteria. Uni- and multivariable Cox proportional hazard models were used to assess prognosis, calculating hazard ratios (HR) with confidence interval (CI). Of the n = 1138 selected patients, n = 95 were histologically classified as ILC and n = 805 as invasive breast cancer of no special type (BC-NST), n = 238 were classified as other breast cancer subtype. In ILC, tumor grade was not associated with DRFS/RFS or OS (HR for DRFS 1.40, 95%CI 0.42-4.63). However, the presence of lymphovascular invasion (LVI) (adjusted HR DRFS 2.81, 95%CI 1.14-6.94, p < 0.05) and multifocality (adjusted HR DRFS 3.28, 95%CI 1.49-7.22, p < 0.01) were. When comparing DRFS, RFS and OS in matched low-risk luminal A-like ILC vs. BC-NST, we observed a trend for worse 15-year survival in ILC (15-year DRFS 63% in ILC vs. 74% in BC-NST; HR 1.50, 95%CI 0.98-2.29, p = 0.06). In these young patients with systemically untreated N0 ILC we show that grade was not prognostic at 15 years follow-up, whereas LVI and multifocality were. Furthermore, ILC had a numerically worse 15-year survival than matched luminal A-like BC-NST.

PMID 42560578
阅读全文 →
PubMedThorax2026-08-06

Implementation and outcomes of drug response assessments for inhaled hypertonic saline in bronchiectasis: a post hoc analysis of the CLEAR trial.

McLeese Rebecca H RH, O'Neill Brenda B, McAuley Daniel F DF, Clarke Mike M et al.

A drug response assessment (DRA) is recommended before starting patients on hypertonic saline (HTS) due to the risk of bronchoconstriction. As part of the CLEAR trial (a randomised, open-label trial of HTS and/or carbocisteine versus usual care in bronchiectasis), we performed a post hoc analysis to explore the implementation and outcomes of DRAs. We aimed to remotely train/assess research coordinators in performing DRAs and determine patient safety/tolerability with HTS. Research coordinators were remotely trained/deemed DRA competent. DRAs were conducted only in patients assigned HTS. Failure was classified as ≥15% forced expiratory volume in 1 s (FEV1) drop or 10%-15% drop with respiratory symptoms. 54 research coordinators (20 sites) were remotely trained/deemed competent, and 52 conducted at least one DRA. 145 patients completed DRAs: 144 were correctly classified, one was misclassified as pass (found during quality checks). 12 were classified as fail in the first DRA: seven had ≥15% FEV1 drop, two had 10%-15% FEV1 drop with symptoms, one had severe coughing (clinical team did not recruit) and the reason was not documented for two. 11 repeated the DRA; nine passed and continued in the trial, two failed and were excluded. 142/145 were classified as pass and entered the trial. Of 142 patients who continued in the trial, 46 later withdrew from HTS. 17 withdrawals were related to issues with HTS tolerance despite passing the first DRA. DRA failure rate was low and did not identify medium-term/long-term tolerance to HTS, indicating that its utility as a screening tool for tolerability in this population is limited. ISRCTN89040295.

PMID 42557060
阅读全文 →
PubMedBritish journal of anaesthesia2026-08-06

κ-Opioid receptor activation suppresses triple-negative breast cancer progression by inducing urea cycle dysfunction and mitochondrial damage in vitro and in mice. Comment on Br J Anaesth 2025; 135: 1803-15.

Shi Yumiao Y, Tao Yiying Y, Pan Zhiying Z, Qian Guojun G et al.

PMID 42557158
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多TJ-15